Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~Individuals eligible to participate in this study must meet the following key criteria and additional criteria as specified in the protocol:~1. Male or female, aged ≥ 18 years~2. Confirmed diagnosis of MM per IMWG criteria~3. Measurable disease as defined by one or more of the following:~   * Serum M-protein ≥ 0.5 g/dL~  * Urine M-protein ≥ 200 mg/24 hours~  * Serum Free Light Chain (FLC) assay: involved FLC level ≥ 10 mg/dL provided serum FLC ratio is abnormal~  * In cases where SPEP is unreliable, serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL) is acceptable~4. Relapsed or refractory (Rajkumar, 2011) to 3 or more different prior lines of therapy for MM, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), chemotherapies, or monoclonal antibodies, and not a candidate for, or intolerant to established therapy known to provide clinical benefit.~5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1~6. Adequate organ and marrow function at Screening, as defined by the study protocol.~Key Exclusion Criteria:~1. Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, Waldenstrom's macroglobulinemia, or IgM myeloma~2. Active plasma cell leukemia (˃ 2.0 × 109/L circulating plasma cells by standard differential)~3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)~4. Prior treatment directed to B-cell Activating Factor (BAFF; BLyS), B-cell Maturation Antigen (BCMA;TNFSF17) or Transmembrane Activator and CAML interactor (TACI; TNFSF13B), including antibodies or BCMA- or TACI-directed Chimeric Antigen Receptor (CAR)-T cell therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BION-1301 (Type: EXPERIMENTAL): BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).